4th EUROPEAN COLORECTAL CANCER DAYS: BRNO 2015 - PREVENTION AND SCREENING 29-30 May 2015, Brno, Czech Republic

COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFE STYLE, SCREENING AND PROPER CARE

CT Colonography and CRC screening: an update

Andrea Laghi M.D.

Dept of Radiological Sciences, Oncology and Pathology "Sapienza", University of Rome Polo Pontino – Latina <u>andrea.laghi@uniroma1.it</u>



SCREENING



POPULATION



dreamraine.com

OPPORTUNISTIC

SCREENING



POPULATION



dreamraime.com

OPPORTUNISTIC

CTC in 2015

- The best radiological test for colon imaging
- Patient-friendly and safe
- Completely replacing BE
- Complimentary to CS



1994 - 2014

- 20th anniversary of CT Colonography
- Presented by DJ Vining at ARRS meeting in 1994 (Am J Roentgenol 1994;62:Suppl:104)



1997: SINGLE-SLICE CTC



2014: MULTISLICE CTC





TECHNIQUE STANDARDIZATION



GASTROINTESTINAL

The second ESGAR consensus statement on CT colonography

Emanuele Neri · Steve Halligan · Mikael Hellström · Philippe Lefere · Thomas Mang · Daniele Regge · Jaap Stoker · Stuart Taylor · Andrea Laghi · ESGAR CT Colonography Working Group

TECHNIQUE

- 1. Bowel prep
- 2. Colon distention
- 3. CT scanning
- 4. Image reviewing

TECHNIQUE: BOWEL PREP

lopamidol Diatrizoate meglumine



Laxative-free

Reduced prep

Low-fiber diet

1L PEG4 tablets bysacodil

90m L

REDUCE PREP/LAXATIVE-FREE

- Partial cleansing (due to osmolarity)
- Iodine-tagged residual fluids and stools



FLUID/FAECAL TAGGING



1) Identification of "submerged" lesions

FLUID/FAECAL TAGGING



2) Characterization of tiny polyps

TECHNIQUE

No SEDATION

- Colon distention (room air/CO₂)
- Two 10s scans
- Overall time, 15 min



COMPUTED ASSISTED DIAGNOSIS

 Software for automatic detection of polyp candidates

2nd read CAD is recommended because it increases sensitivity for polyp detection without an unacceptable decrease in specificity.





Eur Radiol DOI 10.1007/s00330-014-3435-z

GUIDELINE

Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline

Cristiano Spada • Jaap Stoker • Onofre Alarcon • Federico Barbaro • Davide Bellini • Michael Bretthauer • Margriet C. De Haan • Jean-Marc Dumonceau • Monika Ferlitsch • Steve Halligan • Emma Helbren • Mikael Hellstrom • Ernst J. Kuipers • Philippe Lefere • Thomas Mang • Emanuele Neri • Lucio Petruzziello • Andrew Plumb • Daniele Regge • Stuart A. Taylor • Cesare Hassan • Andrea Laghi





Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline ()

Authors

Cristiano Spada¹, Jaap Stoker², Onofre Alarcon³, Federico Barbaro¹, Davide Bellini⁴, Michael Bretthauer⁵, Margriet C. De Haan², Jean-Marc Dumonceau⁶, Monika Ferlitsch², Steve Halligan⁸, Emma Helbren⁸, Mikael Hellstrom⁹, Ernst J. Kuipers¹⁰, Philippe Lefere¹¹, Thomas Mang¹², Emanuele Neri¹³, Lucio Petruzziello¹, Andrew Plumb⁶, Daniele Regge¹⁴, Stuart A. Taylor⁸, Cesare Hassan¹, Andrea Laghi¹⁶

ESGE

Institutions

Institutions are listed at the end of article.



ESGE – ESGAR CTC GUIDELINES



ESGE/ESGAR do not recommend CTC as a primary test for population screening or in subjects with a first-degree positive family history (EL: Moderate ; RG: Weak)

- EFFICACY
- ACCEPTABILITY
- SAFETY
- COST-EFFECTIVENESS
- LOGISTICS

- EFFICACY
- ACCEPTABILITY
- SAFETY
- COST-EFFECTIVENESS
- LOGISTICS

CTC: THE EVIDENCES

RCT	Multi-center trials	Single center trials	Meta-analyses		
			Sosna	Chaparro	
COCOS		Munich	Mulhall	Pickhardt	
SIGGAR	IMPACT	Pickhardt	Halligan	De Haan	
			Rosman	Plumb	

- CTC = CS for CRC and >10 mm polyps
- CTC < CS for 6-9 mm polyps
- CTC << CS for <6 mm polyps

CTC: THE EVIDENCES

RCT	Multi-center trials	Single center trials	Meta-analyses		
			Sosna	Chaparro	
COCOS	ACRIN	Munich	Mulhall	Pickhardt	
SIGGAR	IMPACT	Pickhardt	Halligan	De Haan	
			Rosman	Plumb	

- CTC > FS (only left colon)
- CTC >> FOBT (cancer only)

- EFFICACY
- ACCEPTABILITY
- SAFETY
- COST-EFFECTIVENESS
- LOGISTICS

Exam **ACCEPTABILITY** influences subjects adherence to screening



FOBT adherence: ITALY

Data courtesy of dr Carlo Senore, CPO, Piedmont, Italy



EFFICACY **ADHERENCE EFFICIENCY** (CRC prevention rate)



CT COLONOGRAPHY



CTC adherence in screening

Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial

Esther M Stoop*, Margriet C de Haan*, Thomas R de Wijkerslooth, Patrick M Bossuyt, Marjolein van Ballegooijen, C Yung Nio, Marc J van de Vijver, Katharina Biermann, Maarten Thomeer, Monique E van Leerdam, Paul Fockens, Jaap Stoker, Ernst J Kuipers, Evelien Dekker

www.thelancet.com/oncology Published online November 15, 2011 DOI:10.1016/S1470-2045(11)70283-2



CTC: ADHERENCE RATE

Protéus trial Results RCT: FS vs CS 1984 SUBJECTS RANDOMISED 990 994 ALLOCATED TO THE CTC ALLOCATED TO THE ARM ES ARM CTC: 30.4%
FS: 27.0% 14 DIED OR EMIGRATED **BEFORE RANDOMISATION /** 14 DIED OR EMIGRATED INVITATION BEFORE RANDOMISATION / INVITATION 980 976 INVITED FOR CTC INVITED FOR FS INCLUDED IN THE INCLUDED IN THE ANALYSIS ANALYSIS 264 (27.0%) RESPONDERS Male uptake 649 NON RESPONDERS ELIGIBLE FOR SUBSEQUENT INVITATION 298 (30.4%) RESPONDERS of CTC higher 329 320 INVITED FOR FIT INVITED FOR CTC FIT AFTER 2Y than FS (OR, 16 (4.9%) 19 (5.9%) ATTENDED WITHIN 3 MONTHS ATTENDED WITHIN 3 MONTHS RR: 1.12 0.98-1.29 1.6; 95% CI: 1.1-

2.3; P=0.01)

 "Unfair" comparison between a well-established test and a "new-comer" in a region where population-based CRC screening using FS works



- Further "marketing" of CTC (PCP; public opinion)
 - Among CTC invitees, the following key groups were more likely to uptake screening:
 - male (ORs, 2.4; 95% CI: 1.4-4.1)
 - retired (ORs, 2.10; 95% CI: 1.2-2.7)
 - those asking general practitioner for counseling (ORs, 2.6; 95% CI: 1.3-5.4)

- those having friends/relatives with CRC (ORs, 4.1; 95% CI: 1.6-10.9)

- those who have read information material (ORs, 7.3; 95% CI: 2.6-19.2)

Unexplained higher adherence in males

- Participation rate in males is
 HIGHER (opposite to FS trial)
 - Why ?
 - Are males more scared of an endoscope ?
 - Or are they simply more interested in technological innovations?



 Bowel preparation and level of embarrassment in favor of FS

		FS	СТС	Patient's experience
Bowel preparation	None/very	187	171	-
	mild	80.3%	72.8%	
	Milal	29	22	
	IVIIIO	12.4%	9.4%	
Side effects	Moderate /	17	42	
	severe	7.3%**	17.9%**	
	4	167	152	
	1	71.7%	64.1%	
Level of pain *	² 1.	Prepa	ration I	needs to be improved
	~ 2	36	40	
	>2	15.5%	18.2%	
	1	192	180	
		82.4%	75.9%	
Level of	2	28	40	
anxiety *		12.0%	16.9%	
	>2	13	17	
		5.6%	7.2%	
Level of Embarassm ent *	1	193	175	
		82.8%***	73.8%***	
	2	22	35	** OR (TCT vs FS): 2.77; 95%CI:1.52-5.01 *** OR (TCT vs FS): 0.50: 05%CI:0.37.0.01
		9.4%	14.8%	UK (ICI VSI'S), 0.37, 73 /001;0.37-091
	>2	18	27	
		7.7%	11.4%	1

		FS	СТС	Patient's experience		
Bowel preparation	None/very	187	171	-		
	mild	80.3%	72.8%			
	Mild	29	22			
	IMITO	12.4%	9.4%			
	Moderate /	17	42			
	severe	7.3%**	17.9%**			
Level of pain *	4	167	152			
	1	71.7%	64.1%			
	² 1. Preparation needs to be improved					
	>2	36	40			
		15.5%	18.2%			
	4	192	180			
Level of anxiety *	11. CT room setup is probably not					
	² adequate for screening					
	>2	13	17			
		5.6%	7.2%			
Level of Embarassm ent *	4	193	175			
	I	82.8%***	73.8%***			
	2	22	35	** OR (TCT vs FS): 2.77; 95%CI:1.52-5.01		
		9.4%	14.8%	L 16 vs 26%		
	>2	18	27			
		7.7%	11.4%			



- EFFICACY
- ACCEPTABILITY
- SAFETY
- COST-EFFECTIVENESS
- LOGISTICS

CTC: SAFETY



- Radiation exposure
- Complications (perforations)

Current recommendations



- Reasonably low-dose exam
- Total effective dose: ≈ 5 mSv

2nd ESGAR Consensus Statement on CTC

Benefits clearly outweigh radiation risks
 Risk/benefit: 1:24 / 1:35

Berrington de Gonzalez, AJR, 2010



- New technology (**ITERATIVE** algorithm)
- Dose exposure lower than natural background

Annual radiation background ≈2.5-3.0 mSv CTC (iterative recon) ≈1.5 mSv

- Carcinogenic risk of low-dose radiation exposure IS neither DEMONSTRATED nor SCIENTIFICALLY DEMONSTRABLE
- Beyond LNT, other theories do exhist

Radiation Dose-Response Models

Data and radiation-induced cancer No data

RADIATION RISK IN PERSPECTIVE

There is substantial and convincing scientific evidence for health risks following high-dose exposures. However, below 5–10 rem (which includes occupational and environmental exposures), risks of health effects are either too small to be observed or are nonexistent.

Threshold Background Cancer Rate Adaptive response

Health Physics Society Telephone: 703-790-1745 Fax: 703-790-2672 Email: HPS@BurkInc.com http://www.hps.org







Some facts



American Journal of Epidemiology Copyright © 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 1 Printed in U.S.A. DOI: 10.1093/aje/kwg107

ORIGINAL CONTRIBUTIONS

Mortality from Cancer and Other Causes among Airline Cabin Attendants in Europe: A Collaborative Cohort Study in Eight Countries

Among airline cabin crew in Europe, there was <u>no</u> <u>increase in mortality that could be attributed to</u> <u>cosmic radiation</u> or other occupational exposures to any substantial extent

Iterative Reconstruction: CTC

ASIR 50%















PERFORATION

Eur Radiol DOI 10.1007/s00330-014-3190-1

GASTROINTESTINAL

Perforation rate in CT colonography: a systematic review of the literature and meta-analysis

Davide Bellini • Marco Rengo • Carlo Nicola De Cecco • Franco Iafrate • Cesare Hassan • Andrea Laghi Meta-analysis >100,000 patients

- CS data are underestimated
- Surgical rate: CTC, 0.008% (1:12,500) CS, 100%
- NO CTC-related deaths

B.A. M/65y, F/U



t0

t21d

- EFFICACY
- ACCEPTABILITY
- SAFETY
- COST-EFFECTIVENESS
- LOGISTICS

COST/EFFECTIVENESS OF CTC

СТС	Follow-up Interval	Sensitivity for Cancer, Specificity	Test Costs ^b			
Hassan, 2007 (44)	10 years, all findings	95, 86	97	FSIG, COL	CS	Dominant vs. FSIG, ICER COL vs. CTC: 14,600
Ladabaum, 2004 (53)	10 years, all findings	95, 85	1,037	COL	36,300	Dominated by COL
Pickhardt, 2007 (19)	10 years, findings 6+ mm	95, 86	555	FSIG, COL	5,100	Dominant vs. FSIG, ICER COL vs. CTC: 74200
Somenberg, 2000 (54)	10 years, all findings	80, 95	741	COL	17,800	Dominated by COL
Vijan, 2007 (23)	5 years, all findings	91, 91	707	gFOBT, COL, FSIG, FSIG + gFOBT	10,300-21,800	197,200
Zauber, 2009 (MISCAN) (22)	5 years, findings 6+ mm	84-92, 80-88	522	gFOBT, SENSA, COL, FSIG, FIT, FSIG + gFOBT	9,500–10,200	Dominated by COL, FSIG + gFOBT
Zauber, 2009 (SimCRC) (22)	5 years, findings 6+ mm	84-92, 80-88	522	gFOBT, SENSA, COL, FSIG, FIT, FSIG + gFOBT	3,600-4,200	Dominated by COL, FSIG + gFOBT
Zauber, 2009 (CRC-SPIN) (22)	5 years, findings 6+ mm	84-92, 80-88	522	gFOBT, SENSA, COL, FSIG, FIT, FSIG + gFOBT	1,900-2,100	Dominated by COL, FSIG + gFOBT

CTC dominated by CC, FSIG + gFOBT

COST/EFFECTIVENESS OF CTC

Eur Radiol (2013) 23:897-907 DOI 10.1007/s00330-012-2689-6

GASTROINTESTINAL

Unit costs in population-based colorectal cancer screening using CT colonography performed in university hospitals in The Netherlands

M. C. de Haan • M. Thomeer • J. Stoker • E. Dekker • E. J. Kuipers • M. van Ballegooijen

- Dutch costs of CT-screening were substantially lower than the cost assumptions that were used in published cost-effectiveness analyses on CTC screening
- Average costs per participant: €169.40

- EFFICACY
- ACCEPTABILITY
- SAFETY
- COST-EFFECTIVENESS
- LOGISTICS

Alimentary Pharmacology & Therapeutics



Projected impact of colorectal cancer screening with computerized tomographic colonography on current radiological capacity in Europe

C. HASSAN*, A. LAGHI†, P. J. PICKHARDT‡,§, D. H. KIM‡, A. ZULLO*, F. IAFRATE† & S. MORINI*

28,760,130 European population (30% compliance)



START-UP PERIOD

6.6 CTC/CT unit/day

STEADY STATE

4.3 CTC/CT unit/day





ESGE – ESGAR CTC GUIDELINES



ESGE/ESGAR strongly recommend CTC in the case of **positive FOBT/FIT with incomplete or unfeasible CS** within organized population screening programs. (RG: Strong; EL: Low).



Se for >6 mm polyps is 89% Sp is lower, 75% *"CTC is a good alternative if CS is undesirable"*

Plumb AA et al. Eur Radiol 2014

CTC: integration into FOBT-based CRC screening programs

Patients with +FOBT/FIT refusing CS



Data courtesy of dr Carlo Senore, CPO, Piedmont, Italy

SCREENING





ประเทราที่และอา

POPULATION OPPORTUNISTIC

EFFICACY SAFETY



ESGE – ESGAR CTC GUIDELINES



ESGE/ESGAR ... suggest (CTC) as a CRC screening test on an individual basis providing the screenes are adequately informed about test characteristics, benefits and risks. (EL: Moderate ; RG: Weak) Home | Community | Get Involved | Donate | Contact Us | Site Inde

American

Prevention & Early Detection

My Planner

 Prevention and Early Detection

Prevention

Early Detection

Stories of Hope

Tobacco and Cancer

Great American Smokeout

Food and Fitness

Great American Health Check

Great American Eat Right Challenge

Environmental Carcinogens

The followinc people at av any specific People who different scre

screened mo should see t

Cancer-re

For people a checkup sho and gender. skin, lymph (non-cancere

Consolial tast

Beginning at age 50, both men and women at average risk for developing colorectal cancer should use one of the screening tests below. The tests Americ that are designed to find both early cancer and polyps are preferred if these tests are available to you and you are willing to have one of these more the Ea invasive tests. Talk to your doctor about which test is best for you.

Tests that find polyps and cancer

Colon and rectal cancer

- flexible sigmoidoscopy every 5 years*
- colonoscopy every 10 years
- double contrast barium enema every 5 years*
- CT colonography (virtual colonoscopy) every 5 years*

Tests that mainly find cancer

- fecal occult blood test (FOBT) every year*,**
 - fecal immunochemical test (FIT) every year*
- stool DNA test (sDNA), interval uncertain*





Go≯

Register | Sign In 본







President Obama Gets Virtual Colonoscopy (CT Colonography) Coverage to Seniors PR Newswire 2010-03-02

Medicare Should Cover Screening CT Colonography for Older Americans Who Want It WASHINGTON, Marcl /PRNewswire-USNewswire/ -- President Obama, in his first routine physical exam as commander in chief, received a CT colonography (CTC), commonly known as a virtual colonoscopy, to screen him for colorectal cancer. However, Obama Administration officials at the Centers for Medicare and Medicaid Services (CMS) previously denied coverage of the same exam for seniors enrolled in Medicare, cutting off access for many an exam proven to increase compliance with nationally accepted colon cancer...

CONCLUSIONS

- CTC CANNOT be proposed as a population screening test today
 - Recommendations from EU are for FOBT/FIT
 - Missing data on cost/effectiveness
 - Shortage of radiologists and equipments??
- CTC CAN be integrated in a population screening programme based on FOBT/FIT
 - To replace BE in pts with +FOBT/FIT and incomplete CC
 - To investigate pts with +FOBT/FIT who refuse CC

CONCLUSIONS

- CTC is effective, acceptable and safe as an opportunistic screening test
 - asymptomatic, average-risk subjects; starting @ age 50; time interval, 5 yrs